Skip to main content
Home > Press Releases > Erik von Schenck appointed new Chairman for Airsonett Operating Room Innovation AB

Erik von Schenck appointed new Chairman for Airsonett Operating Room Innovation AB


Press Releases
08 January 13 11:01

Following the separation of Airsonett Operating Room Innovation AB from Airsonett AB, Erik von Schenck has been appointed the company´s new Chairman.

 “Opragon® is a unique ventilation system and it is exciting to be part of forming the future of such an innovative product. My hope is that my experience in the Life Science field will benefit Airsonett ORI AB in a positive way and that we will see the product being accepted by a broader market in the near future” says Erik von Schenck.

Erik von Schenck has many years’ experience from working in the Medical Device and Life Science industry; most recently he joined Physio-Control as Vice President of CPR Products in February, 2011 following the acquisition of Jolife AB.  He had served as CEO at Jolife AB for over six years. Erik spearheads design and development of new products for cardiopulmonary resuscitation.

Previously, Erik was the CEO of Jostra AB, and managed its integration into Getinge AB when the company was acquired.  Before this he held several leading positions within Gambro AB.  He has been working in the Life Science segment since 1991.

Erik is also active as board member of the Medical Device companies Xvivo AB, Sensodetect AB and Captera Medtech AB.

Airsonett ORI AB is a research based medical device company with a unique technology pioneering the decrease of airborne bacteria and virus contamination in health care premises, primarily in operating theatres. The company’s most important product is Opragon. The company is based in Medicon Village, Lund, Sweden.

”Opragon is a relatively new product and we have in a short time established it in Sweden. We have also installed Opragon in a number of hospitals in Europe. In 2012 the legal entity Airsonett ORI AB was formed and Opragon was separated from Airsonett AB.” says Airsonett ORI AB’s CEO Peter Ekolind.

For more information about Airsonett ORI AB and Opragon, please contact:
Peter Ekolind, CEO, Airsonett Operating Room Innovation AB
, Medicon Village, Scheelevägen 2, SE-223 63 Lund, Sweden
Tel: +46 (0)703 415560, e-mail: peter.ekolind@airsonett.com, www.airsonett.com/opragon/

 

The information on this website is intended for residents of the United States only. The product described here is FDA 510(k) cleared for use in the United States. Product indications and availability may differ in other regions.